P2Y 1 [P2 (purinergic type-2)-receptor 1] is a G-protein-coupled ADP receptor that regulates platelet activation and ADP-induced Ca 2+ signalling. Studies using P2Y 1 -knockout mice, G q -deficient mice or P2Y 1 -selective inhibitors have previously identified a key role for P2Y 1 in pathophysiological thrombus formation at high shear stress. We provide evidence that a positively charged juxtamembrane sequence within the cytoplasmic C-terminal tail of P2Y 1 can bind directly to the cytosolic regulatory protein calmodulin. Deletion by mutagenesis of the calmodulin-binding domain of P2Y 1 inhibits intracellular Ca 2+ flux in transfected cells. These results suggest that the interaction of calmodulin with the P2Y 1 C-terminal tail may regulate P2Y 1 -dependent platelet aggregation.
INTRODUCTION
P2Y 1 [P2 (purinergic type-2)-receptor 1] is a G-protein (Gα q )-linked seven-transmembrane receptor of the purinergic receptor family that activates platelets in response to ADP and regulates Ca 2+ -dependent signalling events, initiating shape change and reversible αIIbβ3-dependent aggregation [1, 2] . P2Y 1 -dependent activation is reinforced by a second ADP receptor on platelets, P2Y 12 , which is Gα i -linked and promotes irreversible platelet aggregation [1] [2] [3] . The major evidence for a key pathophysiological role for P2Y 1 in thrombus formation comes from studies in P2Y 1 -deficient mice, G q -deficient mice or normal mice treated with P2Y 1 antagonists such as MRS-2179 or MRS-2500 [4] [5] [6] [7] [8] [9] [10] [11] [12] . Without P2Y 1 (and despite normal P2Y 12 expression), platelets show a decreased propensity to form a stable thrombus. Platelets lacking P2Y 1 aggregate only at high ADP concentrations (via P2Y 12 ), and do so without shape change or elevation of cytosolic Ca 2+ levels. P2Y 1 -null mice show little or no tendency for spontaneous bleeding, but do show markedly increased resistance to thromboembolism in vivo, when induced by intravenous injection of ADP or collagen plus adrenaline [6, 7] . Most recently, it was shown in mice deficient in P2Y 1 , or treated with the P2Y 1 -antagonists MRS-2179 or MRS-2500, that arterial thrombosis was significantly less than controls in FeCl 3 -or laser-induced arterial wall injury models (high-shear conditions); however, venous thrombosis (lower shear) was only slightly inhibited in these models [10, 12] . Combined blockade of P2Y 1 and P2Y 12 is essentially additive when inhibiting thrombus formation under shear stress [8, 10, 12, 13] .
Recent studies support the notion that calmodulin plays a central role in the initiation of platelet thrombus formation. In human platelets, aggregation at high shear stress is triggered by the adhesion receptor GPIb (glycoprotein Ib)-IX-V, which binds von Willebrand factor and initiates thrombus involving other receptors, including the collagen receptor, GPVI, and integrins (chiefly αIIbβ3). Cytoplasmic domains of both GPVI and GPIb-IX-V (subunits GPIbβ and GPV) contain discrete juxtamembrane sequences that directly bind calmodulin, interactions which dissociate upon platelet activation [14] [15] [16] [17] [18] [19] . Engagement of GPIbα (the major ligand-binding subunit of GPIb-IX-V) or GPVI leads to secretion of ADP that acts via P2Y 1 and P2Y 12 to increase αIIbβ3-dependent aggregation. It was shown recently [13] , that GPIbα-dependent thrombus formation on von Willebrand factor at high shear is specifically impaired by P2Y 1 blockade, including elevation of cytosolic Ca 2+ associated with platelet arrest, whereas P2Y 12 blockade inhibited formation of larger aggregates. Together, these studies indicate a key role for P2Y 1 in thrombus formation under conditions of shear stress in flowing blood, and support the promise of P2Y 1 as a future antithrombotic target [1, 3, 9, 11] . The goal of the present study was to determine whether the cytoplasmic domain of P2Y 1 binds calmodulin in the same manner as other receptors with analogous sequences (Figure 1) , and whether the interaction may regulate P2Y 1 -dependent platelet activation.
MATERIALS AND METHODS

General reagents
Amylose-agarose was purchased from New England Biolabs 1 Co-first authors. 2 To whom correspondence should be addressed (email jane.arthur@med.monash.edu.au).
Figure 1 Comparison of calmodulin-binding sequences
Juxtamembrane calmodulin-binding sequence within the P2Y 1 C-terminal cytoplasmic tail, compared with known calmodulin-binding sequences in platelet GPVI [15] [16] [17] , GPIbβ [14] , a non-physiological calmodulin-binding control peptide that forms amphipathic α-helix [20] , leucocyte adhesion receptor, L-selectin [21] and the G-protein-coupled glutamate receptor m7a [22] . Identical residues or conservative substitutions are highlighted. The Gβγ -binding region (residues 857-861) and the site of a deletion (residues 864-876) that blocks calmodulin binding are shown on the m7a sequence [22] compared with the G-protein-binding site at Arg 333 /Arg 334 of P2Y 1 [23] . Asterisks show known PKC-dependent phosphorylation sites in m7a (Ser 862 ) [24] and P2Y 1 (Thr 339 ) [25, 26] .
[
, was the gift of Dr Shaun Jackson (Australian Centre for Blood Diseases, Clayton, Monash University, VIC, Australia).
Gel-shift assay
The capacity of a synthetic peptide based on a P2Y 1 C-terminal tail sequence (R 332 RRLSRATRKASRR 345 ) to form a complex with purified calmodulin was examined using a gel-shift assay previously used to identify calmodulin-binding peptides [13, 14, 19, 21, 22] . Briefly, 0.3 nmol of bovine calmodulin (Sigma, St Louis, MO, U.S.A.) was mixed with 0-3.0 nmol of P2Y 1 peptide in 0.1 M Tris/HCl and 4 M urea, pH 7.5, in the presence of either 1 mM Ca 2+ or 10 mM EGTA. After 30 min at 22
• C, 0.5 vol. of 50 % (v/v) glycerol containing two drops of 0.1 % Bromophenol Blue was added to each sample prior to resolution on 12.5 %-polyacrylamide gels containing 4 M urea, and stained with Coomassie Blue.
Preparation of MBP (maltose-binding protein)-P2Y 1 fusion proteins
cDNA corresponding to the P2Y 1 C-terminal tail sequence (Phe 325 -Leu 373 ) was amplified by PCR from full-length cDNA encoding wild-type human P2Y 1 in a pCDNA3 vector (Invitrogen, Carlsbad, CA, U.S.A.) [6] . Forward and reverse primers included unique restriction sites (EcoR1 and BamH1 respectively) in noncomplementary 5 ends for subcloning of the amplified fragment into an MBP-fusion vector. The PCR fragment was purified using a QIAquick PCR purification kit (Qiagen, Doncaster, VIC, Australia), digested with EcoR1 and BamH1 and inserted into the pMAL-C2X vector (New England Biolabs) encoding MBP N-terminal to the P2Y 1 tail insert. A calmodulin-deletion mutant of MBP-P2Y 1 tail lacking residues Arg 337 -Asn 349 was prepared using a blunt-end ligation method as previously described [27] . The correct sequence of the vectors was confirmed by sequencing. MBP alone, or wild-type or mutant MBP-P2Y 1 C-terminal tail fusion proteins expressed in Escherichia coli strain BL21 were purified on amylose-agarose and dialysed into TS buffer (0.01 M Tris/HCl and 0.15 M NaCl, pH 7.4) using standard methods [15] . Subcloning of wild-type or calmodulin-deleted P2Y 1 tail sequences in GST (glutathione S-transferase) vector (pGEX-4T-1; Amersham Pharmacia), expression and purification of fusion proteins on glutathione-Sepharose was performed using similar methods.
Pull-down assays with P2Y 1 fusion proteins
The ability of the full-length P2Y 1 C-terminal tail expressed as a MBP-fusion protein to bind calmodulin in human platelet cytosol was assessed using a pull-down assay, as previously described [15] . Briefly, MBP alone, MBP-P2Y 1 wild-type C-terminal tail, or MBP-P2Y 1 calmodulin-deletion mutant was incubated with cytosol and rocked for 16 h at 4
• C. An equivalent volume of amylose beads (1:1 suspension in TS buffer) was added, and the mixture incubated for a further 4 h. Beads were washed with TS buffer and immunoblotted with anti-calmodulin antibody (Upstate Biotechnology, Lake Placid, NY, U.S.A.) or anti-MBP antibody (New England Biolabs) as previously described [15] . Pull-downs using GST alone, GST-P2Y 1 wild-type C-terminal tail or GST-P2Y 1 calmodulin-deletion mutant from human platelet lysates [28] with glutathione-Sepharose beads were performed using essentially the same methods, and immunoblotted with anti-Gβ 2 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.). Blots were visualized using ECL ® (enhanced chemiluminescence; Amersham, Bucks., U.K.).
Platelet aggregation
Platelet aggregation was performed in a whole-blood LumiAggregometer (Chrono-Log, Havertown, PA, U.SA) using human citrated platelet-rich plasma as previously described [28] . Aggregation was induced by addition of ADP (5 µM). Samples were preincubated with TS buffer or the calmodulin inhibitor W-7 (50-150 µM) for 3 min at 37
• C, prior to adding ADP. Assay mixtures included the P2Y 12 inhibitor ARC369931MX (50 nM).
Intracellular Ca 2+ measurements
As a functional test of the effect of calmodulin site deletion on ADP responses, intracellular Ca 2+ measurements in 1321N1 cells transfected with either P2Y 1 wild-type or the calmodulin-deleted mutant lacking residues Arg 337 -Asn 349 [recombinant human P2Y 1 in pEGFP-N3 vector (Clontech)] were carried out as described previously [29, 30] .
RESULTS AND DISCUSSION
In the present study we show that the cytosolic regulatory protein calmodulin directly interacts with a juxtamembrane positively charged sequence within the C-terminal cytoplasmic tail of P2Y 1 . We recently reported that two platelet-adhesion receptors, GPIb-IX-V and GPVI, which bind von Willebrand factor or collagen respectively to initiate platelet aggregation, bound directly to calmodulin via positively charged juxtamembrane sequences within their cytoplasmic domains [14, 15] . In view of the functional role of these receptors, it was noteworthy that the G-protein-coupled ADP receptor P2Y 1 , which also initiates platelet aggregation [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 13] , contains an analogous sequence in the juxtamembrane region of its cytoplasmic C-terminal tail (Figure 1 ). This sequence of P2Y 1 contains positively charged and hydrophobic residues spaced in a manner similar to calmodulin-binding sequences in other proteins that form amphipathic helices (reviewed in [31] ). The corresponding juxtamembrane region of the other platelet ADP receptor, P2Y 12 (F 304 RNLSLISMLKCPNSAT 320 ) [32] , does not contain a consensus calmodulin-binding sequence. Other G-protein-coupled receptors contain a calmodulin-binding site in the same region of the cytoplasmic C-terminal tail as P2Y 1 , including the glutamate receptor m7a [22, 24] (Figure 1) .
Calmodulin binds to a P2Y 1 -based peptide
Using a gel-shift assay, a synthetic peptide based on the juxtamembrane sequence of the P2Y 1 C-terminal tail sequence, Arg 332 -Arg 345 (R 332 RRLSRATRKASRR 345 ), was shown to bind calmodulin. The peptide induced a dose-dependent shift in migration of purified bovine calmodulin on polyacrylamide gels in the presence of Ca 2+ , generating a single band representing a calmodulin-peptide complex (Figure 2A ). In contrast, in the presence of EGTA, there was significantly less calmodulin-peptide complex (Figure 2A ), suggesting the calmodulin-P2Y 1 peptide interaction under these conditions is Ca 2+ -dependent.
Calmodulin binds to MBP-P2Y 1 C-terminal tail fusion proteins
We expressed two MBP fusion proteins containing the C-terminal region of P2Y 1 to see whether they could bind calmodulin, as did the P2Y 1 -based synthetic peptide. One of the fusion proteins consisted of MBP-P2Y 1 , which contained the full-length wild-type cytoplasmic tail of P2Y 1 (Phe 325 -Leu 373 ). A second MBP-P2Y 1 fusion protein was a calmodulin-deletion mutant lacking residues Arg 337 -Asn 349 within the calmodulin-binding sequence (MBP-P2Y 1 CaM). This deletion was based on a corresponding calmodulin-deletion mutation previously reported to abolish calmodulin binding of the m7a receptor (Figure 1 ) [24] . The MBP-P2Y 1 wild-type tail, but not the MBP-P2Y 1 CaM mutant, could specifically pull down calmodulin from platelet cytosol as shown by Western blotting precipitates with an anti-calmodulin antibody ( Figure 2B ). MBP alone was used as a specificity control. Blotting the MBP-P2Y 1 wild-type tail and MBP-P2Y 1 CaM pull-down samples with anti-MBP antibody [15] confirmed there was equivalent bait in each lane ( Figure 2B ). These results suggest there is a single calmodulin-binding site in the P2Y 1 C-terminal tail involving residues Arg 337 -Asn 349 . The cytoplasmic tail of seven-transmembrane receptors is involved in G-protein binding, and the calmodulin-binding site of P2Y 1 is proximal to the residues (Arg 333 and Arg 334 ) responsible for G-protein association [23] . We therefore investigated whether deletion of the calmodulin-binding site interferes with binding of G-protein subunits. Probing GST-P2Y 1 wild-type tail and GST-P2Y 1 CaM pull-down samples with an antibody raised against amino acids 1-300 of the N-terminus of human Gβ 2 (Santa Cruz Biotechnology), which recognizes Gβ 1 -Gβ 4 and, to a lesser extent, Gβ 5 , confirmed that the P2Y 1 calmodulin-deleted mutant was still able to bind Gβγ subunits ( Figure 2C ).
Calmodulin inhibition by W-7 inhibits P2Y 1 -dependent platelet aggregation
To determine whether there is a functional role for calmodulin in regulating P2Y 1 receptor function, we first tested the effect of the calmodulin inhibitor W-7 on P2Y 1 -dependent platelet aggregation. Assays were carried out under conditions where the other ADP receptor on platelets, P2Y 12 , was blocked using the P2Y 12 -selective inhibitor AR-C69931MX. This inhibitor is an ATP analogue which selectively blocks the human ADP-receptor P2Y 12 , but has no effect on P2Y 1 [33] . In AR-C69931MX-treated platelets, ADP acts on P2Y 1 and induces reversible aggregation, without P2Y 12 -dependent reinforcement leading to stable aggregates [33] . Aggregation occurs up to ∼ 1 min, but is then reversed. P2Y 1 -dependent platelet aggregation induced by ADP in the presence of AR-C69931MX was inhibited by the calmodulin inhibitor W-7 (50-150 µM), with maximal inhibition at ∼ 150 µM (Figure 3) , concentrations of W-7 previously shown to inhibit other calmodulin-mediated events in platelets or other cells [17, 20, 34, 35] . W-7 has been reported to inhibit Ca 2+ -dependent platelet shape change and aggregation in response to agonists such as collagen via a myosin light-chain kinasedependent mechanism [18, 34, 35] . Accordingly, our results do not mean that W-7 only inhibits P2Y 1 -associated calmodulin, but are consistent with calmodulin playing a critical role in P2Y 1 -dependent aggregation. Figure 4A ). In the presence of 2 mM extracellular Ca 2+ , ADP and 2MeSADP elicited a concentrationdependent increase in intracellular Ca 2+ in wild-type cells, which was strongly inhibited in the P2Y 1 calmodulin-deleted mutants ( Figure 4B ). These data demonstrate that deletion of the calmodulin-binding region from the cytoplasmic tail of P2Y 1 significantly inhibits the increase in intracellular Ca 2+ induced by ADP or 2MeSADP, indicating a requirement for calmodulin in P2Y 1 function.
Calmodulin regulates surface expression of GPVI [17] and GPV of the GPIb-IX-V complex [19] , which initiate thrombus formation at high shear [18] . Calmodulin binding to the C-terminal cytoplasmic domain could also regulate surface expression or internalization of P2Y 1 . Overexpression of P2Y 1 on mouse platelets results in reduced bleeding time and increased reactivity to ADP; these results emphasize the potential importance of receptor expression levels in relation to thrombotic states in humans [36] . Activated P2Y 1 receptors are internalized through a pathway distinct from that of P2Y 12 receptors [30] . Calmodulin dissociation from activated P2Y 1 would provide a mechanism for regulating surface expression, as for G-protein-coupled receptors on other cells [22] .
Together, these results suggest that the interaction of calmodulin with the P2Y 1 C-terminal tail may regulate aspects of P2Y 1 -dependent platelet aggregation. The calmodulin-binding sequence is proximal to functional sites for G-protein association (Arg 333 -Arg 334 ) [23] and PKC (protein kinase C)-dependent phosphorylation (Ser 339 ) [25] in the C-terminal tail of P2Y 1 (Figure 1 ). Further studies are warranted in order to unravel the functional role of calmodulin-mediated events at the cytoplasmic face of P2Y 1 and their relationship to calmodulin-dependent regulation of other receptors that initiate thrombosis.
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